Pemazyre, illustration of tablet form (not a photo of the actual pack)

Illustrative image.

Pemazyre

Pemigatinib

Prescription required

$83850.00

4.5mg · 6 × 14 tablets · 3 months supply

BrandBranded medicine· By Incyte

$27950.00 per month

Strength

How long a supply?

1 month$27950.00 a month
3 months$27950.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$363350a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

4.5mg

9mg

13.5mg

About Pemazyre

Overview

Pemazyre (pemigatinib) is a kinase inhibitor supplied as tablets. It treats adults with previously treated bile duct cancer (cholangiocarcinoma) that cannot be removed surgically, is locally advanced or has spread, and has an FGFR2 fusion or other rearrangement detected by an FDA-approved test. It also treats adults with myeloid/lymphoid neoplasms with an FGFR1 rearrangement that have returned or have not responded to treatment. It works by blocking FGFR proteins involved in signals that can support cancer cell growth and survival.

What it treats

- Previously treated bile duct cancer (cholangiocarcinoma) in adults that cannot be removed by surgery and is locally advanced or has spread to other parts of the body, with an FGFR2 fusion or other rearrangement detected by an FDA-approved test. - Myeloid/lymphoid neoplasms (MLNs) in adults with an FGFR1 rearrangement that have returned after treatment or have not responded to treatment.

Safety information

Side effects

Common side effects reported with Pemazyre include high or low blood phosphate levels, hair loss, nail problems, diarrhoea, constipation, tiredness, changes in taste, nausea, vomiting, mouth sores, dry mouth, dry eyes, dry skin, reduced appetite, abdominal pain, joint pain and back pain. Other common effects reported in people with myeloid/lymphoid neoplasms with FGFR1 rearrangement include rash, anaemia, nosebleeds, pain in the arms or legs, indigestion, blurred vision, swelling of the hands or feet, and dizziness. Contact your doctor urgently if you develop blurred vision or any other changes in vision. Pemazyre can cause retinal problems, including retinal pigment epithelial detachment and fluid-related retinal detachment. Eye examinations are needed before and regularly during treatment, even if you have no visual symptoms. High blood phosphate levels require monitoring because they can lead to mineral deposits in soft tissues and calcium deposits in the skin, including a condition called calciphylaxis. Your doctor may need to interrupt, adjust or stop treatment depending on how severe or persistent this is. Pemazyre can harm an unborn baby. Contact your doctor if you are pregnant or think you may be pregnant. Patients who could conceive a child should use effective contraception.

When to call your doctor

- Seek medical attention immediately for blurred vision or any other new or worsening vision changes.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The FDA label lists no contraindications for Pemazyre. Important precautions include: Pemazyre can cause retinal pigment epithelial detachment, an eye problem. Eye examinations, including optical coherence tomography (OCT), are required before treatment, every 2 months for the first 6 months, and every 3 months thereafter. Any visual symptoms require an urgent eye examination. Pemazyre can raise phosphate levels in the blood, which may lead to mineral or calcium deposits in soft tissues and skin. Phosphate levels must be monitored, and treatment may need to be adjusted, paused or stopped depending on the severity and duration. Pemazyre can harm an unborn baby. Patients who can become pregnant or father a child should use effective contraception. Do not breastfeed during treatment.

Interactions

Avoid taking Pemazyre with medicines that strongly or moderately increase or block the activity of an enzyme called CYP3A. If a medicine that blocks CYP3A cannot be avoided, your prescriber will need to reduce your Pemazyre dose. Ask your doctor to check your other medicines for these interactions.

Using Pemazyre

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label PEMAZYRE (PEMIGATINIB) TABLET [INCYTE CORPORATION] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines